QUASAAR receives FDA APPROVAL
Quality guided by innovation and efficiency
Quasaar is your experienced and reliable partner for all aspects of product development, quality control, stability studies, analytical services and GMP-support. Our competences are focused on the highly regulated pharmaceutical and life science area (GMP). But healthcare, consumer care and food sectors also benefit from Quasaar's own service profile. A high level of experience in the regulated and technical environment as well as a comprehensive competence network guarantee high quality and constant innovation. We accompany you through the lifecycle of your product and support you with analytical services, clinical trials, market launch and long-term marketing of your product. On the Campus in Überherrn we offer 5.000 sqm of ultramodern state-of-the-art laboratories, an innovative and large-volume stability center and a unique development area. There we will initially provide an inspiring and efficient work environment for up to 50 highly qualified employees.
Find out more about our service in the different technical dsiciplines and topics.
AUGUST 2019 QUASAAR receives FDA APPROVAL
Quasaar received official FDA approval for the successful audit this May.
As a next step, in 2020 we aim for the ANVISA certification
Controlled substances, new storage condition & techniques
New storage condition established: climatic condition 55 ° C / 22% r.F.
Storage of controlled substances now possible (safe for controlled substances 50 m3) as well as stress- and ASAP-studies
New laboratory techniques: new detection technology U/HPLC-CAD, polarimetry, special drug release techniques, particle analysis etc.)
- Support to overcome capacity bottlenecks in quality control
- Know-how input for highly sophisticated projects
- Flexible, fast and on-schedule support
- Storage volume for stability studies
- A certified partner and GMP / GSP experienced team
We can help you in a quick and competent manner.
We are happy to contact you personally and introduce our service.